Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15,525 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EZH2: a novel target for cancer treatment.
Duan R, Du W, Guo W. Duan R, et al. Among authors: guo w. J Hematol Oncol. 2020 Jul 28;13(1):104. doi: 10.1186/s13045-020-00937-8. J Hematol Oncol. 2020. PMID: 32723346 Free PMC article. Review.
Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study.
Liu X, Qin S, Wang Z, Xu J, Xiong J, Bai Y, Wang Z, Yang Y, Sun G, Wang L, Zheng L, Xu N, Cheng Y, Guo W, Yu H, Liu T, Lagiou P, Li J. Liu X, et al. Among authors: guo w. J Hematol Oncol. 2017 Sep 5;10(1):153. doi: 10.1186/s13045-017-0521-0. J Hematol Oncol. 2017. PMID: 28870253 Free PMC article.
Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study.
Liu X, Qin S, Wang Z, Xu J, Xiong J, Bai Y, Wang Z, Yang Y, Sun G, Wang L, Zheng L, Xu N, Cheng Y, Guo W, Yu H, Liu T, Lagiou P, Li J. Liu X, et al. Among authors: guo w. J Hematol Oncol. 2018 Jan 9;11(1):5. doi: 10.1186/s13045-017-0545-5. J Hematol Oncol. 2018. PMID: 29316953 Free PMC article.
FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial.
Zhang X, Duan R, Wang Y, Liu X, Zhang W, Zhu X, Chen Z, Shen W, He Y, Wang HQ, Huang M, Wang C, Zhang Z, Zhao X, Qiu L, Luo J, Sheng X, Guo W. Zhang X, et al. Among authors: guo w. Ther Adv Med Oncol. 2022 Jan 13;14:17588359211068737. doi: 10.1177/17588359211068737. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35069808 Free PMC article.
Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients With Asymptomatic Primary Lesion and Synchronous Unresectable Metastases.
Huang M, Yang Y, Li Q, Wang C, Liang L, Zhu X, Zhang W, Chen Z, Huang D, Li W, Zhang X, Zhao X, Qiu L, Geng Q, Yu N, Du W, Sun S, Sheng X, Li X, Guo W. Huang M, et al. Among authors: guo w. Front Oncol. 2022 Jan 31;12:747124. doi: 10.3389/fonc.2022.747124. eCollection 2022. Front Oncol. 2022. PMID: 35174078 Free PMC article.
Epirubicin combined with oxaliplatin and 5-day continuous infusion of 5-fluorouracil as a first-line treatment for metastatic gastric cancer: treatment outcomes and analysis of prognostic factors.
Zhu X, Zhao X, Peng W, Sun S, Cao J, Ji D, Liu X, Wang C, Huang M, Yu H, Guo W, Li J, Yin J. Zhu X, et al. Among authors: guo w. J Cancer Res Clin Oncol. 2015 Jan;141(1):109-18. doi: 10.1007/s00432-014-1754-8. Epub 2014 Jul 18. J Cancer Res Clin Oncol. 2015. PMID: 25035248 Clinical Trial.
15,525 results
You have reached the last available page of results. Please see the User Guide for more information.